Nature

First-line treatment for CLL in the era of targeted therapy

In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted ...
ascopubs.org

Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based ...

This is a retrospective observational study using Optum Clinformatics Data Mart of adult patients with CLL/small lymphocytic lymphoma who received 2L venetoclax- or BTKi-based regimens (January ...
Nature

Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader

Constitutive activation of the B-cell receptor (BCR) signaling pathway is a hallmark of chronic lymphocytic leukemia (CLL), driving the malignant cell survival, proliferation, and interaction with the ...